$2.22 (0%)

Volume: 321.076k

Closed: Jan 27, 2023

Hollow Logo Score: 0.044
Lexicon Pharmaceuticals Stock
$2.22 (0%)

Volume: 321.076k

Closed: Jan 27, 2023

Score Hollow Logo 0.044
NASDAQ:LXRX

Lexicon Pharmaceuticals Stock Price Targets and Analyst Ratings

Be the first to comment on LXRX

LXRX Forecast. What You Should Know.

LXRX Historical Ratings and Targets

FAQ

What are analyst ratings?
Analyst ratings are recommendations made by various stock analysts. Public companies are rated by analysts who monitor their industries. These stock ratings result from a thorough evaluation of a traded company using known metrics such as sales, earnings, and potential catalysts. Read More...

What to keep in mind using analyst ratings?
The best way to use analyst ratings is to supplement your investment research. Please do not rely on them blindly; instead, use them as one tool in your decision-making process. Also, be sure to pay attention to the date of the rating. Analyst ratings can change quickly, and a rating that was accurate six months ago might not be relevant today. Read More...

What is a price target in trading?
A price target is a stock market term used by investors and analysts to indicate the level at which they believe a stock will trade. The price target is based on several factors, including a company's earnings, revenue, and valuation. Determining a price target can be tricky, as it is an estimate and not always accurate. However, it can guide investors looking to buy or sell a stock. Read More...

Unlock All Premium Features! Go Premium! Only $19.90/Month

Unlock the Top 5 candidates in every list
Unlock full Ultimate List Builder
Golden Star lists & Auto Portfolios
Possible Runners & Moving Average lists
Ad-free browsing
Save data in PDF

Hot Stocks To Watch:

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The compan... LXRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT